Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe revision tag on the page has been updated from v3.5.3 to v3.5.4, indicating a new page version. This is a metadata/version update and does not modify the study content or data presented.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays the updated site revision, v3.5.3, replacing the previous v3.5.2; this indicates a software deployment rather than a change to trial information.SummaryDifference0.1%

- Check39 days agoChange Detected- Revision tag updated from v3.5.0 to v3.5.2. This appears to be a minor maintenance update and does not modify study data or visible content.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible changes to study details or navigation.SummaryDifference0.1%

- Check103 days agoChange DetectedAdded Revision: v3.4.2 and removed notices for Revision: v3.4.1 and a government funding status notice. These are administrative site updates and do not affect the study details on the page.SummaryDifference0.5%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.